Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3795 Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumors – A pooled analysis of five clinical trials

Introduction: There is an increasing interest in the role of sex and gender in cancer patients. The impact of sex differences in systemic oncological therapies is still unknown, and there is a lack of evidence, especially in uncommon neoplasms like neuroendocrine tumors (NET).

Conference:

Presenting Author:

Authors: Hernando Cubero J, Roca-Herrera M, Garcia Alvarez A, Raymond E, Kulke M,

Keywords: Sex, Toxicity, Tyrosine Kinase Inhibitor,

#2262 Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome

Introduction: Telotristat ethyl (TE) is a treatment for carcinoid syndrome (CS) diarrhea used in combination with somatostatin analog (SSA) therapy. In the Phase 3, randomized, placebo-controlled, double-blind TELESTAR and TELECAST studies, CS patients received TE at 250 mg 3 times per day (tid), 500 mg tid, or placebo tid in addition to SSAs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Dillon J, Kulke M, Warner R, Bergsland E, Welin S,

Keywords: telotristat ethyl, somatostatin analogs, carcinoid syndrome,

#2038 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Jonathan S

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,

#1941 Integrated Safety Analysis of Telotristat Ethyl in Patients with Carcinoid Heart Disease

Introduction: Release of serotonin by neuroendocrine tumors is associated with carcinoid heart disease (CaHD), which may pose challenges for carcinoid syndrome (CS) treatment.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lapuerta P

Authors: Lapuerta P, Kulke M, Pavel M, Biran T, Fleming R,

Keywords: serotonin, 5-HIAA,

#1940 Impact of Concomitant Medication on Efficacy of Telotristat Ethyl – A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome

Introduction: The tryptophan hydroxylase inhibitor telotristat ethyl (TE) significantly reduced bowel movement (BM) frequency versus placebo (pbo) in patients (pts) with carcinoid syndrome (CS) in the TELESTAR study.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Anthony L, Kulke M, Hörsch D, Bergsland E, Öberg K,

Keywords: serotonin, diarrhea ,